Amplatzer Cardiac Plug for Stroke Prevention in Patients with Atrial Fibrillation and Bigger Left Atrial Appendix Size

Abstract

Left atrial appendage (LAA) dimensions have been shown as an independent predictor of higher risk for stroke in AF patients. Little data exist on the outcomes after LAA closure in patients with nonvalvular atrial fibrillation (NVAF) who have relatively bigger LAA size. This study aims to evaluate the results associated with LAA closure with the Amplatzer cardiac plug (ACP, AGA, St. Jude Medical, Minneapolis, MN) in bigger LAA size. A total of 25 patients with NVAF underwent LAA closure with the ACP device. All patients received short-term (up to 3 months) dual-antiplatelet therapy (clopidogrel and aspirin) after the procedure and aspirin only thereafter. A transesophageal echocardiography was performed in all patients at the 3- and 6-month follow-ups. No patient was lost to follow-up (≥ 12 months in all patients). The mean age, CHA₂DS₂-VASc score, and HAS-BLED score were 66.2 ± 8.79 years; 3.2 ± 1.46 and 2.4 ± 1.0, respectively. The average sizes of the LAA landing zone and ostium were 23.08 ± 5.0 and 24.9 ± 4.4 mm, respectively. The procedure was successful in 23 (92%) patients and was canceled in 2 (8%) patients due to huge LAA dimensions. In 56% of the patients “pull and release” technique is needed to appropriately implant the ACP. During a mean follow-up of 12 months, no cases of periprocedural stroke and no mortality were observed. In patients with NVAF at high risk of cardioembolic events and big LAA size, LAA closure using the ACP device is safe and effective.

Keywords

closure device - big left atrial appendage

• References

• 1 Singer DE, Albers GW, Dalen JE , et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl), 546S-592S
• 2 Investigator SPAF. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84 (2) 527-539
• 3 Connolly SJ, Ezekowitz MD, Yusuf S , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 4 Patel MR, Mahaffey KW, Garg J , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 5 Granger CB, Alexander JH, McMurray JJ , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
• 6 Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol 2013; 167 (4) 1237-1241
• 7 Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145 (1) 105-112.e15
• 8 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373 (9658) 155-166
• 9 Holmes DR, Reddy VY, Turi ZG , et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374 (9689) 534-542
• 10 Beinart R, Heist EK, Newell JB, Holmvang G, Ruskin JN, Mansour M. Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22 (1) 10-15
• 11 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137 (2) 263-272
• 12 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (5) 1093-1100
• 13 Lam YY, Yip GW, Yu CM , et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. Catheter Cardiovasc Interv 2012; 79 (5) 794-800
• 14 Streb W, Szymała M, Kukulski T , et al. Percutaneous closure of the left atrial appendage using the Amplatzer Cardiac Plug in patients with atrial fibrillation: evaluation of safety and feasibility. Kardiol Pol 2013; 71 (1) 8-16
• 15 Urena M, Rodés-Cabau J, Freixa X , et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013; 62 (2) 96-102
• 16 Meerkin D, Butnaru A, Dratva D, Bertrand OF, Tzivoni D. Early safety of the Amplatzer Cardiac Plug™ for left atrial appendage occlusion. Int J Cardiol 2013; 168 (4) 3920-3925
• 17 Faustino A, Paiva L, Providência R , et al. Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: a single-center experience. Rev Port Cardiol 2013; 32 (6) 461-471
• 18 Taina M, Vanninen R, Hedman M , et al. Left atrial appendage volume increased in more than half of patients with cryptogenic stroke. PLoS ONE 2013; 8 (11) e79519
• 19 Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011; 123 (4) 417-424
• 20 Blessing R, Nikolai P, Schnorbus B, Munzel T, Von Bardeleben R, Gori T. Outcome after anticoagulant versus double antiplatelet therapy after left atrial appendage closure (EuroPCR Proceeding, OP308); 2014. Available at: http://www.pcronline.com/eurointervention/AbstractsEuroPCR2014/europcr-abstracts-andposters-2014/OP308/outcome-after-anticoagulant-versus-double-antiplatelet-therapy-after-left-atrial-appendage-closure.html . Accessed June 12, 2015
• 21 Schlundt C, Scheuermann S, Marwan M, Schuhbaeck A, Ludwig J, Achenbach S. Left atrial appendage closure (WATCHMAN™) after bleeding complications during oral anticoagulant therapy in high risk patients. J Indian Coll Cardiol 2014; 5: 25-28